Clinical Trials | October 25, 2025
Sanofi’s Efdoralprin Alfa shows superiority in phase 2 Alpha-1 antitrypsin deficiency study
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
Subscribe To Our Newsletter & Stay Updated
